Myxofibrosarcoma

Myxofibrosarcoma
SpecialtyDermatology, Dermatopathology, Pathology, Surgical oncology, Oncology
TypesEpithelioid myxofibrosarcoma
CausesUnknown
PrognosisGuarded

Myxofibrosarcoma (MFS), although a rare type of tumor, is one of the most common soft tissue sarcomas, i.e. cancerous tumors, that develop in the soft tissues of elderly individuals.[1] Initially considered to be a type of histiocytoma termed fibrous histiocytoma or myxoid variant of malignant fibrous histiocytoma,[2] Angervall et al. termed this tumor myxofibrosarcoma in 1977.[3] In 2020, the World Health Organization reclassified MFS as a separate and distinct tumor[4] in the category of malignant fibroblastic and myofibroblastic tumors.[5]

MFS tumors are often treated by surgical resection. However, these tumors have high recurrence rates at the sites of their resections.[6] Local recurrences followed by surgical resections may be repeated multiple times but during these cycles MFS tumors often progress from a lower grade to a higher more aggressive grade, metastasize, and become life-threatening.[4] An uncommon variant of the MFS tumors termed epithelioid myxofibrosarcoma is even more likely to follow an aggressive, recurrent, metastasizing, and life-threatening course than the more common form of the MFS tumors.[6]

  1. ^ Martínez-Trufero J, Cruz Jurado J, Gómez-Mateo MC, Bernabeu D, Floría LJ, Lavernia J, Sebio A, García Del Muro X, Álvarez R, Correa R, Hernández-León CN, Marquina G, Hindi N, Redondo A, Martínez V, Asencio JM, Mata C, Valverde Morales CM, Martin-Broto J (September 2021). "Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I". Cancer Treatment Reviews. 99: 102259. doi:10.1016/j.ctrv.2021.102259. ISSN 0305-7372. PMID 34311246.
  2. ^ Weiss SW, Enzinger FM (April 1977). "Myxoid variant of malignant fibrous histiocytoma". Cancer. 39 (4): 1672–85. doi:10.1002/1097-0142(197704)39:4<1672::aid-cncr2820390442>3.0.co;2-c. PMID 192434. S2CID 29351227.
  3. ^ Angervall L, Kindblom LG, Merck C (March 1977). "Myxofibrosarcoma. A study of 30 cases". Acta Pathologica et Microbiologica Scandinavica, Section A. 85A (2): 127–40. doi:10.1111/j.1699-0463.1977.tb00410.x. PMID 15396.
  4. ^ a b Gilg MM, Sunitsch S, Leitner L, Bergovec M, Szkandera J, Leithner A, Liegl-Atzwanger B (October 2020). "Tumor-associated mortality and prognostic factors in myxofibrosarcoma - A retrospective review of 109 patients". Orthopaedics & Traumatology, Surgery & Research. 106 (6): 1059–1065. doi:10.1016/j.otsr.2020.04.017. PMID 32778437. S2CID 225432867.
  5. ^ Sbaraglia M, Bellan E, Dei Tos AP (April 2021). "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives". Pathologica. 113 (2): 70–84. doi:10.32074/1591-951X-213. PMC 8167394. PMID 33179614.
  6. ^ a b Hornick JL (December 2018). "Subclassification of pleomorphic sarcomas: How and why should we care?". Annals of Diagnostic Pathology. 37: 118–124. doi:10.1016/j.anndiagpath.2018.10.006. PMID 30340082. S2CID 53008610.